Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Diabetes Care Publish Ahead of Print published online ahead of print July 20, 2007
DOI: 10.2337/dc07-0066

This Article
Right arrow Full Text (PDF)
Right arrow Online-Only Appendix
Right arrow All Versions of this Article:
dc07-0066v1
dc07-0066v2
30/10/2583    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tsuchiyama, N.
Right arrow Articles by Kato, K.-i.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tsuchiyama, N.
Right arrow Articles by Kato, K.-i.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Original Research

Possible role of alpha cell insulin resistance in exaggerated glucagon responses to arginine in type 2 diabetes

Naomi Tsuchiyama, MD, Toshinari Takamura, MD, PHD, Hitoshi Ando, MD, PHD, Masaru Sakurai, MD, Akiko Shimizu, MD and Ken-ichiro Kato, MD

Disease Control and Homeostasis, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan

ttakamura{at}m-kanazawa.jp

ABSTRACT

OBJECTIVE–: Inappropriate excessive secretion of glucagon, which contributes to postprandial hyperglycemia, is a novel target for the treatment of diabetes. In this study, we sought to determine the factors associated with exaggerated glucagon secretion in response to an arginine challenge in patients with type 1 and type 2 diabetes.

RESEARCH DESIGN AND METHODS–: Changes in circulating C-peptide immunoreactivity (CPR) and immunoreactive glucagon (IRG) after an arginine challenge were investigated in 35 patients with type 1 diabetes, 130 patients with type 2 diabetes, and 35 non-diabetic control subjects.

RESULTS–: No significant differences were found in the basal level and the area under the concentration–time curve (AUC) of IRG (AUCIRG) among type 1 and type 2 diabetic patients and non-diabetic subjects. However, the correlation between the AUCIRG and the AUC of CPR (AUCCPR) was inverse between type 1 (r = –0.388, P = 0.023) and type 2 diabetic patients (r = 0.396, P < 0.0001), whereas AUCIRG was not correlated with AUCCPR in non-diabetic subjects (r = -0.079, P = 0.655). In type 1 diabetic patients, the AUCCPR decreased and the AUCIRG increased with increasing disease duration. In type 2 diabetic patients, both AUCIRG and AUCCPR increased with increasing BMI, basal CPR level, and homeostatic model assessment of insulin resistance (HOMA-IR) value.

CONCLUSIONS–: Our findings suggest that the pathophysiology of the exaggerated glucagon response differs between the types of diabetes. Intra-islet insulin deficiency and alpha cell insulin resistance may be the primary contributors to this condition in type 1 and type 2 diabetes, respectively.


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
P. Bansal and Q. Wang
Insulin as a physiological modulator of glucagon secretion
Am J Physiol Endocrinol Metab, October 1, 2008; 295(4): E751 - E761.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2007 by the American Diabetes Association.